MLN2480

Research use only, not for human use.

MLN2480 is an oral, selective pan-Raf kinase inhibitor in Clinicalal trials.

TAK-580, also known as MLN2480, BIIB024, and AMG 2112819, is an oral, selective pan-Raf kinase inhibitor. The Raf kinases (A-Raf, B-Raf and C-Raf) are key regulators of cell proliferation and survival within the mitogen-activated protein kinase (MAPK) pathway. The MAPK pathway is frequently disregulated in human cancers, often via activating mutations of Ras or Raf.

——

——

TAK-580, TAK 580, TAK580, MLN 2480, MLN-2480, MLN2480

TGF-beta/Smad

TGFBR

Raf

Cancer

——

1096708-71-2

506.29

C17H12Cl2F3N7O2S

>98% (HPLC)

DMSO : 50 mg/mL 98.76 mM;

Nc1ncnc(C(=O)N[C@H](C)c2ncc(C(=O)Nc3ncc(Cl)c(C(F)(F)F)c3)s2)c1Cl

(R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide

(-20℃)

With Ice Pack

≥ 2 years